Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hot Flashes | 74 | 2023 | 316 | 11.850 |
Why?
|
Menopause | 80 | 2024 | 1626 | 8.190 |
Why?
|
Perimenopause | 29 | 2022 | 139 | 6.320 |
Why?
|
Estradiol | 33 | 2023 | 2017 | 5.380 |
Why?
|
Women's Health | 36 | 2024 | 2033 | 3.580 |
Why?
|
Sleep Initiation and Maintenance Disorders | 22 | 2022 | 1004 | 3.190 |
Why?
|
Postmenopause | 33 | 2022 | 2458 | 2.760 |
Why?
|
Estrogen Replacement Therapy | 17 | 2022 | 1203 | 2.510 |
Why?
|
Depression | 42 | 2024 | 7760 | 2.210 |
Why?
|
Cyclohexanols | 7 | 2015 | 127 | 2.090 |
Why?
|
Depressive Disorder | 14 | 2018 | 3744 | 1.830 |
Why?
|
Sleep | 33 | 2023 | 4619 | 1.830 |
Why?
|
Progesterone | 7 | 2022 | 773 | 1.470 |
Why?
|
Menstrual Cycle | 7 | 2020 | 551 | 1.410 |
Why?
|
Vasomotor System | 13 | 2022 | 209 | 1.370 |
Why?
|
Gonadotropin-Releasing Hormone | 5 | 2016 | 1205 | 1.290 |
Why?
|
Premenstrual Syndrome | 4 | 2017 | 109 | 1.260 |
Why?
|
Citalopram | 12 | 2018 | 403 | 1.200 |
Why?
|
Affect | 10 | 2021 | 1473 | 1.070 |
Why?
|
Hypothalamo-Hypophyseal System | 6 | 2023 | 703 | 1.040 |
Why?
|
Sleep Deprivation | 4 | 2023 | 831 | 1.000 |
Why?
|
Menstruation Disturbances | 3 | 2012 | 148 | 0.910 |
Why?
|
Ethinyl Estradiol | 3 | 2017 | 116 | 0.900 |
Why?
|
Sweating | 10 | 2018 | 123 | 0.890 |
Why?
|
Estrogens | 12 | 2022 | 1563 | 0.890 |
Why?
|
Androstenes | 2 | 2017 | 168 | 0.840 |
Why?
|
Female | 167 | 2024 | 380020 | 0.830 |
Why?
|
Estrone | 4 | 2022 | 240 | 0.780 |
Why?
|
Leuprolide | 4 | 2016 | 321 | 0.750 |
Why?
|
Premenopause | 8 | 2022 | 1033 | 0.750 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2022 | 323 | 0.740 |
Why?
|
Follicle Stimulating Hormone | 10 | 2022 | 745 | 0.740 |
Why?
|
Anxiety | 15 | 2023 | 4288 | 0.740 |
Why?
|
Irritable Mood | 1 | 2021 | 183 | 0.700 |
Why?
|
Antidepressive Agents | 9 | 2018 | 2837 | 0.700 |
Why?
|
Valproic Acid | 4 | 2008 | 445 | 0.700 |
Why?
|
Bipolar Disorder | 10 | 2011 | 5027 | 0.680 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2022 | 629 | 0.680 |
Why?
|
Middle Aged | 107 | 2023 | 213241 | 0.670 |
Why?
|
Chickens | 1 | 2021 | 864 | 0.670 |
Why?
|
Hydrocortisone | 2 | 2023 | 1826 | 0.640 |
Why?
|
Double-Blind Method | 28 | 2023 | 12020 | 0.630 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2022 | 841 | 0.620 |
Why?
|
Longitudinal Studies | 31 | 2022 | 13980 | 0.620 |
Why?
|
Quality of Life | 18 | 2023 | 12788 | 0.610 |
Why?
|
Brain-Derived Neurotrophic Factor | 1 | 2021 | 604 | 0.610 |
Why?
|
Pituitary-Adrenal System | 5 | 2023 | 553 | 0.600 |
Why?
|
Fertility Agents, Female | 2 | 2016 | 99 | 0.590 |
Why?
|
Humans | 173 | 2024 | 743811 | 0.580 |
Why?
|
Appetite | 1 | 2018 | 244 | 0.570 |
Why?
|
Anti-Mullerian Hormone | 2 | 2020 | 402 | 0.540 |
Why?
|
Adult | 81 | 2024 | 213889 | 0.530 |
Why?
|
Ovary | 3 | 2015 | 980 | 0.520 |
Why?
|
Hypnotics and Sedatives | 4 | 2011 | 1161 | 0.510 |
Why?
|
Actigraphy | 6 | 2022 | 488 | 0.500 |
Why?
|
Yoga | 7 | 2018 | 252 | 0.480 |
Why?
|
Depressive Disorder, Major | 9 | 2024 | 4635 | 0.470 |
Why?
|
Fatigue | 3 | 2021 | 1530 | 0.470 |
Why?
|
Breast Neoplasms | 9 | 2023 | 20827 | 0.460 |
Why?
|
Adiposity | 3 | 2020 | 1806 | 0.460 |
Why?
|
Arousal | 1 | 2019 | 1160 | 0.450 |
Why?
|
Polycystic Ovary Syndrome | 3 | 2008 | 370 | 0.430 |
Why?
|
Polysomnography | 7 | 2021 | 1776 | 0.430 |
Why?
|
Medicine | 1 | 2021 | 945 | 0.430 |
Why?
|
Patient Participation | 1 | 2022 | 1457 | 0.430 |
Why?
|
Pandemics | 3 | 2021 | 8385 | 0.420 |
Why?
|
Sleep Stages | 1 | 2016 | 685 | 0.420 |
Why?
|
Antimanic Agents | 2 | 2006 | 522 | 0.420 |
Why?
|
Cardiovascular System | 1 | 2019 | 828 | 0.400 |
Why?
|
Contraceptives, Oral | 2 | 2020 | 564 | 0.400 |
Why?
|
Mood Disorders | 4 | 2009 | 1104 | 0.400 |
Why?
|
Hyperandrogenism | 3 | 2006 | 38 | 0.390 |
Why?
|
Medroxyprogesterone Acetate | 1 | 2012 | 163 | 0.390 |
Why?
|
Energy Metabolism | 2 | 2022 | 2899 | 0.390 |
Why?
|
Patient Compliance | 2 | 2018 | 2683 | 0.390 |
Why?
|
Sleep Disorders, Intrinsic | 1 | 2010 | 15 | 0.380 |
Why?
|
Academic Medical Centers | 1 | 2021 | 2760 | 0.370 |
Why?
|
Azabicyclo Compounds | 2 | 2009 | 68 | 0.370 |
Why?
|
Anxiety Disorders | 4 | 2019 | 2684 | 0.360 |
Why?
|
Hormones | 4 | 2023 | 889 | 0.360 |
Why?
|
Contraceptives, Oral, Combined | 2 | 2017 | 113 | 0.360 |
Why?
|
Weight Gain | 2 | 2018 | 2294 | 0.360 |
Why?
|
Placebos | 12 | 2018 | 1674 | 0.360 |
Why?
|
Benzhydryl Compounds | 1 | 2016 | 844 | 0.350 |
Why?
|
Wakefulness | 1 | 2016 | 1243 | 0.340 |
Why?
|
Puerperal Disorders | 2 | 2009 | 275 | 0.340 |
Why?
|
Age of Onset | 1 | 2016 | 3268 | 0.330 |
Why?
|
Vaginal Diseases | 3 | 2020 | 102 | 0.330 |
Why?
|
Reproduction | 2 | 2020 | 666 | 0.330 |
Why?
|
Luteinizing Hormone | 3 | 2021 | 867 | 0.320 |
Why?
|
gamma-Aminobutyric Acid | 3 | 2015 | 1118 | 0.310 |
Why?
|
Health Surveys | 3 | 2016 | 4036 | 0.310 |
Why?
|
Saliva | 2 | 2023 | 809 | 0.310 |
Why?
|
Health Status | 5 | 2018 | 4031 | 0.310 |
Why?
|
Thiophenes | 2 | 2013 | 589 | 0.290 |
Why?
|
Hypothalamus | 1 | 2012 | 1061 | 0.280 |
Why?
|
Pregnanediol | 2 | 2021 | 18 | 0.280 |
Why?
|
Fatty Acids, Omega-3 | 6 | 2018 | 1344 | 0.270 |
Why?
|
Oligomenorrhea | 1 | 2006 | 45 | 0.270 |
Why?
|
Amenorrhea | 2 | 2008 | 485 | 0.270 |
Why?
|
Hysterectomy | 5 | 2020 | 927 | 0.260 |
Why?
|
Gonadal Hormones | 2 | 2015 | 29 | 0.260 |
Why?
|
Metabolism | 1 | 2006 | 196 | 0.250 |
Why?
|
Gynecology | 1 | 2020 | 512 | 0.250 |
Why?
|
Serotonin | 1 | 2009 | 1017 | 0.240 |
Why?
|
Treatment Outcome | 25 | 2023 | 63042 | 0.240 |
Why?
|
Psychiatric Status Rating Scales | 9 | 2020 | 6030 | 0.240 |
Why?
|
Ovarian Neoplasms | 1 | 2021 | 4839 | 0.240 |
Why?
|
Vagina | 3 | 2018 | 825 | 0.230 |
Why?
|
Climacteric | 2 | 2002 | 57 | 0.230 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2017 | 1813 | 0.230 |
Why?
|
United States | 24 | 2022 | 69859 | 0.230 |
Why?
|
Ovariectomy | 5 | 2020 | 661 | 0.220 |
Why?
|
Mental Health | 3 | 2024 | 3012 | 0.220 |
Why?
|
Exercise | 8 | 2018 | 5611 | 0.210 |
Why?
|
Cyclohexanecarboxylic Acids | 1 | 2003 | 141 | 0.210 |
Why?
|
Meditation | 3 | 2021 | 240 | 0.210 |
Why?
|
Biomedical Research | 3 | 2020 | 3308 | 0.210 |
Why?
|
Antidepressive Agents, Second-Generation | 3 | 2018 | 503 | 0.210 |
Why?
|
Postpartum Period | 1 | 2009 | 1086 | 0.210 |
Why?
|
Severity of Illness Index | 11 | 2019 | 15526 | 0.210 |
Why?
|
Cognition | 6 | 2023 | 6759 | 0.210 |
Why?
|
Acetates | 1 | 2003 | 310 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3134 | 0.210 |
Why?
|
Calorimetry, Indirect | 1 | 2022 | 183 | 0.210 |
Why?
|
Pyridines | 2 | 2011 | 2827 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3241 | 0.200 |
Why?
|
Amines | 1 | 2003 | 276 | 0.200 |
Why?
|
Piperazines | 2 | 2009 | 2487 | 0.200 |
Why?
|
Follicular Phase | 1 | 2021 | 152 | 0.200 |
Why?
|
Prospective Studies | 16 | 2024 | 53250 | 0.190 |
Why?
|
Hormone Replacement Therapy | 2 | 2022 | 708 | 0.190 |
Why?
|
Paroxetine | 2 | 2015 | 181 | 0.190 |
Why?
|
Psychotropic Drugs | 1 | 2007 | 893 | 0.190 |
Why?
|
Anti-Anxiety Agents | 1 | 2003 | 390 | 0.190 |
Why?
|
Body Temperature Regulation | 2 | 2012 | 252 | 0.190 |
Why?
|
Infertility, Female | 1 | 2007 | 788 | 0.180 |
Why?
|
Child Abuse | 2 | 2023 | 1030 | 0.180 |
Why?
|
Carbohydrates | 1 | 2022 | 394 | 0.180 |
Why?
|
Hyperprolactinemia | 2 | 2013 | 129 | 0.180 |
Why?
|
Risk Factors | 19 | 2021 | 72252 | 0.180 |
Why?
|
Epilepsy | 2 | 2008 | 3284 | 0.180 |
Why?
|
Men's Health | 1 | 2020 | 70 | 0.180 |
Why?
|
Azepines | 1 | 2022 | 334 | 0.180 |
Why?
|
Sleep Arousal Disorders | 1 | 2019 | 11 | 0.180 |
Why?
|
Young Adult | 10 | 2022 | 56392 | 0.180 |
Why?
|
Drug Therapy, Combination | 4 | 2017 | 6487 | 0.170 |
Why?
|
Glucocorticoids | 1 | 2009 | 2107 | 0.170 |
Why?
|
Ovulation | 1 | 2020 | 189 | 0.170 |
Why?
|
Stress, Psychological | 6 | 2024 | 4245 | 0.170 |
Why?
|
Cross-Sectional Studies | 10 | 2022 | 25032 | 0.170 |
Why?
|
Career Mobility | 1 | 2021 | 262 | 0.160 |
Why?
|
Sex Factors | 4 | 2021 | 10394 | 0.160 |
Why?
|
Menopause, Premature | 1 | 2020 | 132 | 0.160 |
Why?
|
Complementary Therapies | 1 | 2022 | 485 | 0.160 |
Why?
|
Tumor Escape | 1 | 2021 | 350 | 0.160 |
Why?
|
Recurrence | 4 | 2016 | 8337 | 0.160 |
Why?
|
Efficiency | 1 | 2021 | 462 | 0.160 |
Why?
|
Cohort Studies | 12 | 2021 | 40545 | 0.150 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2020 | 3480 | 0.150 |
Why?
|
Administration, Cutaneous | 3 | 2011 | 710 | 0.150 |
Why?
|
Self Report | 7 | 2022 | 3550 | 0.150 |
Why?
|
Odds Ratio | 6 | 2022 | 9848 | 0.150 |
Why?
|
Cardiovascular Diseases | 6 | 2022 | 15142 | 0.150 |
Why?
|
Anticonvulsants | 2 | 2008 | 1910 | 0.150 |
Why?
|
Mental Health Services | 1 | 2009 | 1643 | 0.150 |
Why?
|
Women's Rights | 1 | 2017 | 69 | 0.150 |
Why?
|
Logistic Models | 4 | 2018 | 13404 | 0.150 |
Why?
|
Affective Symptoms | 2 | 2011 | 405 | 0.150 |
Why?
|
Psychotic Disorders | 2 | 2009 | 3044 | 0.140 |
Why?
|
Oxidation-Reduction | 1 | 2022 | 2183 | 0.140 |
Why?
|
Follow-Up Studies | 13 | 2021 | 39001 | 0.140 |
Why?
|
Adolescent | 12 | 2021 | 85729 | 0.140 |
Why?
|
Triazoles | 1 | 2022 | 904 | 0.140 |
Why?
|
Circadian Rhythm | 4 | 2022 | 2620 | 0.140 |
Why?
|
Sex Characteristics | 3 | 2021 | 2583 | 0.140 |
Why?
|
Mentors | 1 | 2021 | 631 | 0.140 |
Why?
|
Cerebral Cortex | 1 | 2012 | 5692 | 0.130 |
Why?
|
Migraine Disorders | 1 | 2008 | 1620 | 0.130 |
Why?
|
Pennsylvania | 1 | 2016 | 613 | 0.130 |
Why?
|
Immunity | 1 | 2021 | 1013 | 0.130 |
Why?
|
Gender Identity | 1 | 2020 | 686 | 0.120 |
Why?
|
Galvanic Skin Response | 2 | 2013 | 349 | 0.120 |
Why?
|
Decision Making, Computer-Assisted | 1 | 2015 | 150 | 0.120 |
Why?
|
Age Factors | 8 | 2020 | 18355 | 0.120 |
Why?
|
HIV Infections | 2 | 2018 | 16715 | 0.120 |
Why?
|
Body Mass Index | 6 | 2020 | 12718 | 0.120 |
Why?
|
Androgens | 1 | 2021 | 1247 | 0.110 |
Why?
|
Sexual Behavior | 2 | 2014 | 2049 | 0.110 |
Why?
|
Feasibility Studies | 1 | 2023 | 5078 | 0.110 |
Why?
|
Exercise Therapy | 2 | 2018 | 904 | 0.110 |
Why?
|
Antipsychotic Agents | 3 | 2013 | 3057 | 0.110 |
Why?
|
Granulosa Cells | 1 | 2013 | 121 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2020 | 9944 | 0.110 |
Why?
|
Interview, Psychological | 1 | 2016 | 812 | 0.110 |
Why?
|
Telephone | 1 | 2016 | 617 | 0.110 |
Why?
|
Adult Survivors of Child Abuse | 1 | 2016 | 260 | 0.110 |
Why?
|
Faculty, Medical | 1 | 2021 | 1181 | 0.110 |
Why?
|
Prevalence | 4 | 2022 | 15211 | 0.110 |
Why?
|
Blood Pressure Determination | 1 | 2016 | 633 | 0.110 |
Why?
|
Menorrhagia | 1 | 2012 | 63 | 0.110 |
Why?
|
Blood Pressure | 2 | 2019 | 8551 | 0.100 |
Why?
|
Caregivers | 1 | 2024 | 2098 | 0.100 |
Why?
|
Hospitalization | 2 | 2009 | 10259 | 0.100 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2020 | 1523 | 0.100 |
Why?
|
Cytochrome P-450 CYP2D6 | 1 | 2012 | 106 | 0.100 |
Why?
|
Leadership | 1 | 2021 | 1357 | 0.100 |
Why?
|
Mental Disorders | 2 | 2009 | 6593 | 0.100 |
Why?
|
Forecasting | 1 | 2021 | 2950 | 0.100 |
Why?
|
Research Design | 2 | 2020 | 5983 | 0.100 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2014 | 386 | 0.100 |
Why?
|
Placebo Effect | 1 | 2015 | 503 | 0.100 |
Why?
|
Internet | 1 | 2023 | 3058 | 0.100 |
Why?
|
Case-Control Studies | 5 | 2021 | 21733 | 0.100 |
Why?
|
Single-Blind Method | 3 | 2015 | 1586 | 0.100 |
Why?
|
C-Reactive Protein | 1 | 2022 | 3778 | 0.090 |
Why?
|
Bone Remodeling | 1 | 2014 | 569 | 0.090 |
Why?
|
Aged | 11 | 2022 | 163178 | 0.090 |
Why?
|
Adipose Tissue | 1 | 2022 | 3280 | 0.090 |
Why?
|
Delayed-Action Preparations | 1 | 2013 | 967 | 0.090 |
Why?
|
Menarche | 2 | 2017 | 516 | 0.090 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2018 | 1872 | 0.090 |
Why?
|
Depression, Postpartum | 2 | 2006 | 340 | 0.090 |
Why?
|
Lithium Compounds | 1 | 2011 | 225 | 0.090 |
Why?
|
Medication Adherence | 1 | 2020 | 2063 | 0.080 |
Why?
|
Monitoring, Ambulatory | 1 | 2012 | 358 | 0.080 |
Why?
|
Socioeconomic Factors | 3 | 2020 | 7784 | 0.080 |
Why?
|
Hyperhidrosis | 1 | 2008 | 35 | 0.080 |
Why?
|
Heart Rate | 2 | 2019 | 4091 | 0.080 |
Why?
|
Monitoring, Physiologic | 2 | 2015 | 1738 | 0.080 |
Why?
|
Psychometrics | 1 | 2017 | 3000 | 0.080 |
Why?
|
Multicenter Studies as Topic | 1 | 2013 | 1676 | 0.080 |
Why?
|
Dementia | 1 | 2022 | 2518 | 0.080 |
Why?
|
Obesity | 3 | 2020 | 12744 | 0.080 |
Why?
|
Primary Ovarian Insufficiency | 2 | 2018 | 115 | 0.080 |
Why?
|
Testosterone | 3 | 2021 | 2297 | 0.080 |
Why?
|
Time Factors | 8 | 2020 | 40038 | 0.080 |
Why?
|
Patient Satisfaction | 2 | 2014 | 3391 | 0.070 |
Why?
|
Glycogen | 2 | 2018 | 259 | 0.070 |
Why?
|
Dietary Supplements | 3 | 2015 | 3292 | 0.070 |
Why?
|
Lipoproteins | 1 | 2012 | 881 | 0.070 |
Why?
|
Lactobacillus | 2 | 2018 | 189 | 0.070 |
Why?
|
Hirsutism | 1 | 2006 | 69 | 0.070 |
Why?
|
Aging | 3 | 2020 | 8655 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2016 | 10940 | 0.070 |
Why?
|
Electroencephalography | 1 | 2021 | 6061 | 0.070 |
Why?
|
Self Concept | 1 | 2012 | 1024 | 0.070 |
Why?
|
Regression Analysis | 1 | 2016 | 6457 | 0.070 |
Why?
|
Dyspareunia | 2 | 2018 | 50 | 0.070 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2024 | 5445 | 0.070 |
Why?
|
Statistics, Nonparametric | 1 | 2011 | 2883 | 0.060 |
Why?
|
Incidence | 4 | 2022 | 20948 | 0.060 |
Why?
|
Behavior Therapy | 1 | 2010 | 862 | 0.060 |
Why?
|
Gonadal Steroid Hormones | 1 | 2009 | 710 | 0.060 |
Why?
|
Comorbidity | 5 | 2018 | 10380 | 0.060 |
Why?
|
Cross-Over Studies | 1 | 2009 | 2029 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 2 | 2015 | 6539 | 0.060 |
Why?
|
Administration, Oral | 1 | 2012 | 3912 | 0.060 |
Why?
|
Pregnancy | 7 | 2023 | 29140 | 0.060 |
Why?
|
Triglycerides | 1 | 2012 | 2453 | 0.060 |
Why?
|
Endometrium | 1 | 2007 | 423 | 0.060 |
Why?
|
Hypoglycemic Agents | 1 | 2016 | 2877 | 0.060 |
Why?
|
Risk Assessment | 2 | 2021 | 23327 | 0.060 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2012 | 2016 | 0.060 |
Why?
|
Hyperplasia | 1 | 2007 | 1185 | 0.060 |
Why?
|
Terminology as Topic | 1 | 2010 | 1546 | 0.060 |
Why?
|
Male | 9 | 2022 | 349776 | 0.050 |
Why?
|
Cognition Disorders | 2 | 2010 | 4041 | 0.050 |
Why?
|
Social Support | 1 | 2012 | 2118 | 0.050 |
Why?
|
Predictive Value of Tests | 2 | 2012 | 15067 | 0.050 |
Why?
|
Environment | 1 | 2009 | 1121 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 5230 | 0.050 |
Why?
|
Confidence Intervals | 2 | 2009 | 2971 | 0.050 |
Why?
|
Radiopharmaceuticals | 1 | 2012 | 2647 | 0.050 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5319 | 0.050 |
Why?
|
Washington | 1 | 2022 | 314 | 0.050 |
Why?
|
Disease Progression | 1 | 2018 | 13273 | 0.050 |
Why?
|
Androstenedione | 1 | 2021 | 130 | 0.050 |
Why?
|
Consensus | 2 | 2021 | 2954 | 0.050 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2022 | 275 | 0.050 |
Why?
|
Illinois | 1 | 2020 | 119 | 0.050 |
Why?
|
Glucose | 1 | 2012 | 4398 | 0.040 |
Why?
|
Parity | 2 | 2017 | 929 | 0.040 |
Why?
|
Chicago | 1 | 2020 | 240 | 0.040 |
Why?
|
Biology | 1 | 2022 | 295 | 0.040 |
Why?
|
Health Behavior | 1 | 2011 | 2634 | 0.040 |
Why?
|
Attitude to Health | 1 | 2008 | 2052 | 0.040 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 1 | 2006 | 1951 | 0.040 |
Why?
|
Waist-Hip Ratio | 1 | 2020 | 516 | 0.040 |
Why?
|
Insulin Resistance | 1 | 2012 | 3863 | 0.040 |
Why?
|
Prescriptions | 1 | 2021 | 387 | 0.040 |
Why?
|
Bone Density | 1 | 2011 | 3460 | 0.040 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 2021 | 546 | 0.040 |
Why?
|
Retrospective Studies | 5 | 2021 | 77410 | 0.040 |
Why?
|
Thinking | 1 | 2021 | 317 | 0.040 |
Why?
|
Vulvar Diseases | 1 | 2018 | 61 | 0.040 |
Why?
|
Preoperative Period | 1 | 2020 | 550 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2020 | 15281 | 0.040 |
Why?
|
Genotype | 1 | 2012 | 12944 | 0.040 |
Why?
|
Osteoporosis | 1 | 2007 | 1577 | 0.040 |
Why?
|
Bone and Bones | 1 | 2008 | 2576 | 0.040 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2020 | 355 | 0.040 |
Why?
|
Factor Analysis, Statistical | 1 | 2019 | 975 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2021 | 13112 | 0.040 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2017 | 188 | 0.030 |
Why?
|
Proportional Hazards Models | 1 | 2011 | 12354 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6237 | 0.030 |
Why?
|
Teaching Materials | 1 | 2016 | 86 | 0.030 |
Why?
|
Docosahexaenoic Acids | 2 | 2014 | 877 | 0.030 |
Why?
|
Prefrontal Cortex | 1 | 2006 | 2147 | 0.030 |
Why?
|
Lactation | 1 | 2017 | 411 | 0.030 |
Why?
|
Overweight | 1 | 2006 | 2371 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2012 | 8939 | 0.030 |
Why?
|
Postoperative Period | 1 | 2020 | 1841 | 0.030 |
Why?
|
Orgasm | 1 | 2014 | 61 | 0.030 |
Why?
|
Community-Based Participatory Research | 1 | 2016 | 214 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2021 | 3503 | 0.030 |
Why?
|
Algorithms | 1 | 2015 | 13869 | 0.030 |
Why?
|
Procollagen | 1 | 2014 | 185 | 0.030 |
Why?
|
Menstruation | 1 | 2015 | 302 | 0.030 |
Why?
|
Australia | 1 | 2016 | 1167 | 0.030 |
Why?
|
Atrophy | 1 | 2018 | 1577 | 0.030 |
Why?
|
Neuropsychological Tests | 1 | 2006 | 6976 | 0.030 |
Why?
|
Neoplasms | 1 | 2022 | 21675 | 0.030 |
Why?
|
Reference Values | 1 | 2020 | 4974 | 0.030 |
Why?
|
Follicle Stimulating Hormone, Human | 1 | 2012 | 25 | 0.030 |
Why?
|
Inflammation | 2 | 2023 | 10629 | 0.030 |
Why?
|
Pregnancy Complications | 1 | 2007 | 2861 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2022 | 3208 | 0.030 |
Why?
|
Child | 5 | 2023 | 77637 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 2 | 2012 | 35409 | 0.030 |
Why?
|
Multivariate Analysis | 3 | 2012 | 12243 | 0.030 |
Why?
|
Analysis of Variance | 1 | 2021 | 6356 | 0.030 |
Why?
|
Linear Models | 2 | 2012 | 5952 | 0.030 |
Why?
|
Pain | 1 | 2007 | 4987 | 0.030 |
Why?
|
Humidity | 1 | 2012 | 197 | 0.020 |
Why?
|
Collagen Type I | 1 | 2014 | 592 | 0.020 |
Why?
|
Patient Selection | 2 | 2014 | 4210 | 0.020 |
Why?
|
Selection Bias | 1 | 2013 | 371 | 0.020 |
Why?
|
Quality Control | 1 | 2014 | 841 | 0.020 |
Why?
|
Pilot Projects | 1 | 2024 | 8316 | 0.020 |
Why?
|
Models, Psychological | 1 | 2015 | 807 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2006 | 12954 | 0.020 |
Why?
|
Hypogonadism | 1 | 2016 | 752 | 0.020 |
Why?
|
Schizophrenia | 1 | 2009 | 6865 | 0.020 |
Why?
|
Blood Glucose | 2 | 2016 | 6259 | 0.020 |
Why?
|
Electrodes | 1 | 2012 | 616 | 0.020 |
Why?
|
Eicosapentaenoic Acid | 1 | 2014 | 581 | 0.020 |
Why?
|
Social Environment | 1 | 2015 | 1022 | 0.020 |
Why?
|
Animals | 1 | 2021 | 168660 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2021 | 3583 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2016 | 2712 | 0.020 |
Why?
|
Laboratories | 1 | 2012 | 462 | 0.020 |
Why?
|
Glucuronides | 1 | 2007 | 20 | 0.020 |
Why?
|
Psychological Tests | 1 | 2010 | 647 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2018 | 2715 | 0.020 |
Why?
|
Prognosis | 2 | 2020 | 29052 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2014 | 2369 | 0.020 |
Why?
|
Massachusetts | 2 | 2013 | 8660 | 0.020 |
Why?
|
Educational Status | 1 | 2015 | 2540 | 0.020 |
Why?
|
Norethindrone | 1 | 2006 | 59 | 0.020 |
Why?
|
Survival Rate | 1 | 2021 | 12786 | 0.020 |
Why?
|
Primary Health Care | 1 | 2002 | 4556 | 0.020 |
Why?
|
Immunotherapy | 1 | 2021 | 4437 | 0.020 |
Why?
|
Rh-Hr Blood-Group System | 1 | 1965 | 65 | 0.020 |
Why?
|
Bone Marrow Examination | 1 | 1965 | 157 | 0.020 |
Why?
|
Hospitals, Psychiatric | 1 | 2007 | 332 | 0.020 |
Why?
|
Erythroblastosis, Fetal | 1 | 1965 | 60 | 0.020 |
Why?
|
Risk | 1 | 2017 | 9677 | 0.020 |
Why?
|
Acid-Base Equilibrium | 1 | 1965 | 185 | 0.020 |
Why?
|
Marital Status | 1 | 2006 | 437 | 0.020 |
Why?
|
Sweden | 1 | 2007 | 1341 | 0.010 |
Why?
|
Blood Chemical Analysis | 1 | 1965 | 440 | 0.010 |
Why?
|
Societies, Medical | 1 | 2015 | 3740 | 0.010 |
Why?
|
Pain Measurement | 1 | 2012 | 3420 | 0.010 |
Why?
|
Peptides | 1 | 2014 | 4406 | 0.010 |
Why?
|
Brain | 1 | 2009 | 26345 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2014 | 5096 | 0.010 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2016 | 3338 | 0.010 |
Why?
|
Homeostasis | 1 | 2012 | 3337 | 0.010 |
Why?
|
Decision Making | 1 | 2015 | 3887 | 0.010 |
Why?
|
Epidemiologic Methods | 1 | 2006 | 1364 | 0.010 |
Why?
|
Memory | 1 | 2010 | 2173 | 0.010 |
Why?
|
Body Composition | 1 | 2009 | 2401 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2017 | 19894 | 0.010 |
Why?
|
Blood Transfusion | 1 | 1965 | 1301 | 0.010 |
Why?
|
Models, Biological | 1 | 2015 | 9582 | 0.010 |
Why?
|
Software | 1 | 2012 | 4440 | 0.010 |
Why?
|
Fetus | 1 | 1965 | 1880 | 0.010 |
Why?
|
Plasmapheresis | 1 | 1978 | 211 | 0.010 |
Why?
|
Insulin | 1 | 2012 | 6584 | 0.010 |
Why?
|
Antibodies | 1 | 1965 | 2459 | 0.010 |
Why?
|
Life Style | 1 | 2008 | 3833 | 0.010 |
Why?
|
Motor Activity | 1 | 2006 | 2714 | 0.010 |
Why?
|
Mothers | 1 | 2006 | 2166 | 0.010 |
Why?
|
Patient Readmission | 1 | 2007 | 3117 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2016 | 11729 | 0.010 |
Why?
|
Hypercholesterolemia | 1 | 1978 | 1151 | 0.010 |
Why?
|
Registries | 1 | 2007 | 8090 | 0.010 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2005 | 4266 | 0.000 |
Why?
|
Heart Conduction System | 1 | 1946 | 1047 | 0.000 |
Why?
|
Tachycardia, Ventricular | 1 | 1946 | 1272 | 0.000 |
Why?
|
Arrhythmias, Cardiac | 1 | 1946 | 2267 | 0.000 |
Why?
|
Lipoproteins, LDL | 1 | 1978 | 642 | 0.000 |
Why?
|
Lipoproteins, HDL | 1 | 1978 | 640 | 0.000 |
Why?
|
Homozygote | 1 | 1978 | 1787 | 0.000 |
Why?
|
Heart | 1 | 1946 | 4460 | 0.000 |
Why?
|
Electrocardiography | 1 | 1946 | 6441 | 0.000 |
Why?
|
Cholesterol | 1 | 1978 | 2922 | 0.000 |
Why?
|
Infant, Newborn | 1 | 1965 | 25609 | 0.000 |
Why?
|
Brugada Syndrome | 1 | 1946 | 98 | 0.000 |
Why?
|
Child, Preschool | 1 | 1978 | 40964 | 0.000 |
Why?
|